evaluating effectivness of Plasma rich in growth factor (PRGF) in the treatment of melasma

Comparision of efficacy of 4% hydroquinone alone and combined with Plasma rich in growth factor (PRGF) in the treatment of melasma

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20221016056188N1

Enrollment

Registered

2022-11-02

Start date

2022-11-10

Completion date

Unknown

Last updated

2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

melasma. other melanin hyperpigmentation

Interventions

Intervention 1: Intervention group: combination 4% hydroquinone (Shafa-Iran manufacturing company) locally once a day and injection of plasma rich in growth factor (PRGF) by injection once every two

Eligibility

Sex/Gender

Female

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: female patients with minimum age 18 years old and maximum age 50 years old patients with diagnosed melasma

Exclusion criteria

Exclusion criteria: pregnancy lactation OCPusers history of allergy to the components of formulation

Design outcomes

Primary

Measure	Time frame
Melasma severity. Timepoint: at the begining of the study ( before intervention) and 4,8 , 12 weeks after intervention. Method of measurement: According to Melasma Area and Severity index score.;Patients satisfaction. Timepoint: 4, 8, 12 weeks after begining of the intervention. Method of measurement: Using Patients Global Assessment score.;Physician satisfaction. Timepoint: 4, 8, 12 weeks after begining of the intervention. Method of measurement: Using Physician Global Assessment score.	—

Measure

Time frame

Melasma severity. Timepoint: at the begining of the study ( before intervention) and 4,8 , 12 weeks after intervention. Method of measurement: According to Melasma Area and Severity index score.;Patients satisfaction. Timepoint: 4, 8, 12 weeks after begining of the intervention. Method of measurement: Using Patients Global Assessment score.;Physician satisfaction. Timepoint: 4, 8, 12 weeks after begining of the intervention. Method of measurement: Using Physician Global Assessment score.

—

Secondary

Measure	Time frame
Erythema. Timepoint: At the begining of the study ( before intervention) and 4,8,12 weeks after begining of the intervention. Method of measurement: By physical examination and classification of the complications severity into mild, moderate and severe.;Swelling. Timepoint: 4,8,12 weeks after begining of the intervention. Method of measurement: By physical examination and classification of the complications severity into mild, moderate and severe.;Burning. Timepoint: 4,8,12 weeks after begining of the intervention. Method of measurement: According to the expression of the patient's feelings and classification of the complications severity into mild, moderate and severe.;Dryness. Timepoint: At the begining of the study ( before intervention) and 4,8,12 weeks after begining of the intervention. Method of measurement: By physical examination and classification of the complications severity into mild, moderate and severe.	—

Measure

Time frame

Erythema. Timepoint: At the begining of the study ( before intervention) and 4,8,12 weeks after begining of the intervention. Method of measurement: By physical examination and classification of the complications severity into mild, moderate and severe.;Swelling. Timepoint: 4,8,12 weeks after begining of the intervention. Method of measurement: By physical examination and classification of the complications severity into mild, moderate and severe.;Burning. Timepoint: 4,8,12 weeks after begining of the intervention. Method of measurement: According to the expression of the patient's feelings and classification of the complications severity into mild, moderate and severe.;Dryness. Timepoint: At the begining of the study ( before intervention) and 4,8,12 weeks after begining of the intervention. Method of measurement: By physical examination and classification of the complications severity into mild, moderate and severe.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactRezvan Amiri

Kerman University of Medical Sciences

rezvanamiri1358@yahoo.com+98 34 3132 8328

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026